E Michael Lewiecki1. 1. New Mexico Clinical Research & Osteoporosis Center, 300 Oak St. NE, Albuquerque, NM, 87106, USA. mlewiecki@gmail.com.
Abstract
PURPOSE OF REVIEW: Treat-to-target (goal-directed therapy) has been proposed as a strategy to assist clinicians in selecting the most appropriate initial treatment for osteoporosis and guiding subsequent decisions to continue, change, or stop treatment. This is a review of the current medical evidence regarding treatment targets and potential clinical applications in managing patients with osteoporosis. RECENT FINDINGS: Analyses of randomized placebo-controlled trials of approved agents to treat osteoporosis have generally shown that larger increases in bone mineral density are associated with greater reduction in fracture risk. Achievement of T-scores > -2.5 to -2.0 with treatment appears to provide little additional fracture protection. The paradigm of treat-to-target is aimed at enhancing and individualizing the care of patients with osteoporosis. Based on the best available data, the most promising target is T-score > -2.5. More data are needed to validate the clinical utility of treat-to-target for osteoporosis.
PURPOSE OF REVIEW: Treat-to-target (goal-directed therapy) has been proposed as a strategy to assist clinicians in selecting the most appropriate initial treatment for osteoporosis and guiding subsequent decisions to continue, change, or stop treatment. This is a review of the current medical evidence regarding treatment targets and potential clinical applications in managing patients with osteoporosis. RECENT FINDINGS: Analyses of randomized placebo-controlled trials of approved agents to treat osteoporosis have generally shown that larger increases in bone mineral density are associated with greater reduction in fracture risk. Achievement of T-scores > -2.5 to -2.0 with treatment appears to provide little additional fracture protection. The paradigm of treat-to-target is aimed at enhancing and individualizing the care of patients with osteoporosis. Based on the best available data, the most promising target is T-score > -2.5. More data are needed to validate the clinical utility of treat-to-target for osteoporosis.
Authors: William D Leslie; Lisa M Lix; Helena Johansson; Anders Oden; Eugene McCloskey; John A Kanis Journal: J Bone Miner Res Date: 2012-06 Impact factor: 6.741
Authors: M C Hochberg; P D Ross; D Black; S R Cummings; H K Genant; M C Nevitt; E Barrett-Connor; T Musliner; D Thompson Journal: Arthritis Rheum Date: 1999-06
Authors: Marc C Hochberg; Susan Greenspan; Richard D Wasnich; Paul Miller; Desmond E Thompson; Philip D Ross Journal: J Clin Endocrinol Metab Date: 2002-04 Impact factor: 5.958
Authors: Dennis M Black; Douglas C Bauer; Ann V Schwartz; Steven R Cummings; Clifford J Rosen Journal: N Engl J Med Date: 2012-05-09 Impact factor: 91.245
Authors: Matthew Austin; Yu-Ching Yang; Eric Vittinghoff; Silvano Adami; Steven Boonen; Douglas C Bauer; Gerolamo Bianchi; Michael A Bolognese; Claus Christiansen; Richard Eastell; Andreas Grauer; Federico Hawkins; David L Kendler; Beatriz Oliveri; Michael R McClung; Ian R Reid; Ethel S Siris; Jose Zanchetta; Cristiano A F Zerbini; Cesar Libanati; Steven R Cummings Journal: J Bone Miner Res Date: 2012-03 Impact factor: 6.741
Authors: Dennis M Black; Ian R Reid; Steven Boonen; Christina Bucci-Rechtweg; Jane A Cauley; Felicia Cosman; Steven R Cummings; Trisha F Hue; Kurt Lippuner; Peter Lakatos; Ping Chung Leung; Zulema Man; Ruvie Lou Maria Martinez; Monique Tan; Mary Ellen Ruzycky; Guoqin Su; Richard Eastell Journal: J Bone Miner Res Date: 2012-02 Impact factor: 6.741
Authors: S Ferrari; J D Adachi; K Lippuner; C Zapalowski; P D Miller; J-Y Reginster; O Törring; D L Kendler; N S Daizadeh; A Wang; C D O'Malley; R B Wagman; C Libanati; E M Lewiecki Journal: Osteoporos Int Date: 2015-06-12 Impact factor: 4.507
Authors: William D Leslie; Sumit R Majumdar; Lisa M Lix; Suzanne N Morin; Helena Johansson; Anders Odén; Eugene V McCloskey; John A Kanis Journal: J Bone Miner Res Date: 2014 Impact factor: 6.741
Authors: S Ferrari; C Libanati; Celia Jow Fang Lin; J P Brown; F Cosman; E Czerwiński; L H de Gregόrio; J Malouf-Sierra; J-Y Reginster; A Wang; R B Wagman; E M Lewiecki Journal: J Bone Miner Res Date: 2019-05-29 Impact factor: 6.741